Summary
Abbott Laboratories reported significant revenue growth in the second quarter and first six months of 2017, primarily driven by the acquisition of St. Jude Medical. Net sales increased by 24.4% to $6.637 billion for the quarter and 27.0% to $12.972 billion for the six-month period, largely attributable to the integration of St. Jude Medical's cardiovascular and neuromodulation businesses. Despite the top-line growth, profitability was impacted by higher amortization expenses related to the St. Jude Medical acquisition, leading to a decrease in operating earnings for the quarter. However, the company's strategic portfolio management, including the divestiture of the Abbott Medical Optics (AMO) business and ongoing progress towards acquiring Alere Inc., demonstrates a focus on optimizing its business segments. Investors should monitor the integration costs and synergies expected from the St. Jude Medical acquisition and the progress of the Alere acquisition, which is anticipated to close by the end of the third quarter of 2017.
Financial Highlights
51 data points| Revenue | $6.64B |
| Cost of Revenue | $3.17B |
| Gross Profit | $3.06B |
| SG&A Expenses | $2.15B |
| Operating Expenses | $6.25B |
| Operating Income | $386.00M |
| Interest Expense | $214.00M |
| Net Income | $283.00M |
| EPS (Basic) | $0.16 |
| EPS (Diluted) | $0.16 |
| Shares Outstanding (Basic) | 1.74B |
| Shares Outstanding (Diluted) | 1.75B |
Key Highlights
- 1Net sales increased by 24.4% to $6.637 billion for the three months ended June 30, 2017, and by 27.0% to $12.972 billion for the six months ended June 30, 2017.
- 2The significant revenue growth was primarily driven by the acquisition of St. Jude Medical, which closed on January 4, 2017.
- 3Operating earnings decreased to $427 million for the three months ended June 30, 2017, from $816 million in the prior year, impacted by higher amortization expenses related to the St. Jude Medical acquisition.
- 4The company completed the sale of its Abbott Medical Optics (AMO) business to Johnson & Johnson in February 2017, recognizing a pre-tax gain of $1.151 billion.
- 5Abbott is proceeding with the acquisition of Alere Inc., with an expected closing by the end of the third quarter of 2017, following an amendment to the purchase price.
- 6Goodwill increased significantly to $22.132 billion from $7.683 billion due to the St. Jude Medical acquisition.
- 7Cash and cash equivalents decreased to $9.675 billion from $18.620 billion, largely due to funding the cash portion of the St. Jude Medical acquisition.